Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities

Nucleic Acids Research

Volumn 33, Issue 6, 2005, Pages 1913-1923

  Langlois, Marc André ^a   Beale, Rupert C L ^a   Conticello, Silvestro G ^a   Neuberger, Michael S ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTIDINE; CYTIDINE DEAMINASE; GENE PRODUCT; VIF PROTEIN; VIRUS DNA; ANTIRETROVIRUS AGENT; APOBEC3C PROTEIN, HUMAN; APOBEC3F PROTEIN, HUMAN; CEM15 PROTEIN, HUMAN; CYTOSINE DEAMINASE; DEAMINASE; HYBRID PROTEIN; PROTEIN; REPRESSOR PROTEIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DEAMINATION; DNA REPLICATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINE LEUKEMIA VIRUS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; SENSITIVITY ANALYSIS; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; ENZYME SPECIFICITY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINE LEUKEMIA VIRUS;

AMINO ACID SUBSTITUTION; ANTI-RETROVIRAL AGENTS; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; HUMANS; LEUKEMIA VIRUS, MURINE; NUCLEOSIDE DEAMINASES; PROTEINS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SUBSTRATE SPECIFICITY;

EID: 17144432313     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gki343     Document Type: Article

References (65)

1. Sheehy,A.M., Gaddis,N.C., Choi,J.D. and Malim,M.H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 418, 646-650.
2. Marin,M., Rose,K.M., Kozak,S.L. and Kabat,D. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Med., 9, 1398-1403.
3. Stopak,K., de Noronha,C., Yonemoto,W. and Greene,W.C. (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell, 12, 591-601.
4. Sheehy,A.M., Gaddis,N.C. and Malim,M.H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Med., 9, 1404-1407.
5. Yu,X., Yu,Y., Liu,B., Luo,K., Kong,W., Mao,P. and Yu,X.F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science, 302, 1056-1060.
6. Conticello,S.G., Harris,R.S. and Neuberger,M.S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol., 13, 2009-2013.
7. Schrofelbauer,B., Chen,D. and Landau,N.R. (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl Acad. Sci. USA, 101, 3927-3932.
8. Xu,H., Svarovskaia,E.S., Barr,R., Zhang,Y., Khan,M.A., Strebel,K. and Pathak,V.K. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl Acad. Sci. USA, 101, 5652-5657.
9. Bogerd,H.P., Doehle,B.P., Wiegand,H.L. and Cullen,B.R. (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl Acad. Sci. USA, 101, 3770-3774.
10. Mangeat,B., Turelli,P., Liao,S. and Trono,D. (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem., 279, 14481-14483.
11. Alce,T.M. and Popik,W. (2004) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem., 279, 34083-34086.
12. Cen,S., Guo,F., Niu,M., Saadatmand,J., Deflassieux,J. and Kleiman,L. (2004) The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem., 279, 33177-33184.
13. Douaisi,M., Dussart,S., Courcoul,M., Bessou,G., Vigne,R. and Decroly,E. (2004) HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem. Biophys. Res. Commun., 321, 566-573.
14. Luo,K., Liu,B., Xiao,Z., Yu,Y., Yu,X., Gorelick,R. and Yu,X.F. (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol., 78, 11841-11852.
15. Schafer,A., Bogerd,H.P. and Cullen,B.R. (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology, 328, 163-168.
16. Harris,R.S., Bishop,K.N., Sheehy,A.M., Craig,H.M., Petersen-Mahrt,S.K., Watt,I.N., Neuberger,M.S. and Malim,M.H. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell, 113, 803-809.
17. Mangeat,B., Turelli,P., Caron,G., Friedli,M., Perrin,L. and Trono,D. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature, 424, 99-103.
18. Yu,Q., Konig,R., Pillai,S., Chiles,K., Kearney,M., Palmer,S., Richman,D., Coffin,J.M. and Landau,N.R. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nature Struct. Mol. Biol., 11, 435-442.
19. Lecossier,D., Bouchonnet,F., Clavel,F. and Hance,A.J. (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science, 300, 1112.
20. Zhang,H., Yang,B., Pomerantz,R.J., Zhang,C., Arunachalam,S.C. and Gao,L. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature, 424, 94-98.
21. Harris,R.S., Petersen-Mahrt,S.K. and Neuberger,M.S. (2002) RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell, 10, 1247-1253.
22. Mariani,R., Chen,D., Schrofelbauer,B., Navarro,F., Konig,R., Bollman,B., Munk,C., Nymark-McMahon,H. and Landau,N.R. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell, 114, 21-31.
23. Vartanian,J.P., Meyerhans,A., Asjo,B. and Wain-Hobson,S. (1991) Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol., 65, 1779-1788.
24. Fitzgibbon,J.E., Mazar,S. and Dubin,D.T. (1993) A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res. Hum. Retroviruses, 9, 833-838.
25. Borman,A.M., Quillent,C., Charneau,P., Kean,K.M. and Clavel,F. (1995) A highly defective HIV-1 group O provirus: Evidence for the role of local sequence determinants in G→A hypermutation during negative-strand viral DNA synthesis. Virology, 208, 601-609.
26. Janini,M., Rogers,M., Birx,D.R. and McCutchan,F.E. (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J. Virol., 75, 7973-7986.
27. Vartanian,J.P., Henry,M. and Wain-Hobson,S. (2002) Sustained G→A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J. Gen. Virol., 83, 801-805.
28. Zheng,Y.H., Irwin,D., Kurosu,T., Tokunaga,K., Sata,T. and Peterlin,B.M. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol., 78, 6073-6076.
29. Yu,Q., Chen,D., Konig,R., Mariani,R., Unutmaz,D. and Landau,N.R. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem., 279, 53379-53386.
30. Wiegand,H.L., Doehle,B.P., Bogerd,H.P. and Cullen,B.R. (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO Rep., 23, 2451-2458.
31. Liddament,M.T., Brown,W.L., Schumacher,A.J. and Harris,R.S. (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol., 14, 1385-1391.
32. Gaddis,N.C., Sheehy,A.M., Ahmad,K.M., Swanson,C.M., Bishop,K.N., Beer,B.E., Marx,P.A., Gao,F., Bibollet-Ruche,F., Hahn,B.H. et al. (2004) Further investigation of simian immunodeficiency virus Vif function in human cells. J. Virol., 78, 12041-12046.
33. Bishop,K.N., Holmes,R.K., Sheehy,A.M., Davidson,N.O., Cho,S.J. and Malim,M.H. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol., 14, 1392-1396.
34. Jarmuz,A., Chester,A., Bayliss,J., Gisbourne,J., Dunham,I., Scott,J. and Navaratnam,N. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics, 79, 285-296.
35. Zhang,J. and Webb,D.M. (2004) Rapid evolution of primate antiviral enzyme APOBEC3G. Hum. Mol. Genet., 13, 1785-1791.
36. Conticello,S.G., Thomas,C.J., Petersen-Mahrt,S. and Neuberger,M.S. (2004) Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol., 22, 367-377.
37. Wedekind,J.E., Dance,G.S., Sowden,M.P. and Smith,H.C. (2003) Messenger RNA editing in mammals: New members of the APOBEC family seeking roles in the family business. Trends Genet., 19, 207-216.
38. Yamanaka,S., Poksay,K.S., Balestra,M.E., Zeng,G.Q. and Innerarity,T.L. (1994) Cloning and mutagenesis of the rabbit ApoB mRNA editing protein. A zinc motif is essential for catalytic activity, and noncatalytic auxiliary factor(s) of the editing complex are widely distributed. J. Biol. Chem., 269, 21725-21734.
39. Navaratnam,N., Bhattacharya,S., Fujino,T., Patel,D., Jarmuz,A.L. and Scott,J. (1995) Evolutionary origins of apoB mRNA editing: Catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site. Cell, 81, 187-195.
40. MacGinnitie,A.J., Anant,S. and Davidson,N.O. (1995) Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J. Biol. Chem., 270, 14768-14775.
41. Betts,L., Xiang,S., Short,S.A., Wolfenden,R. and Carter,C.W.,Jr (1994) Cytidine deaminase. The 2.3 Å crystal structure of an enzyme: transition-state analog complex. J. Mol. Biol., 235, 635-656.
42. Carlow,D.C., Carter,C.W.,Jr, Mejlhede,N., Neuhard,J. and Wolfenden,R. (1999) Cytidine deaminases from B. subtilis and E. coli: Compensating effects of changing zinc coordination and quaternary structure. Biochemistry (Mosc.), 38, 12258-12265.
43. Ireton,G.C., McDermott,G., Black,M.E. and Stoddard,B.L. (2002) The structure of Escherichia coli cytosine deaminase. J. Mol. Biol., 315, 687-697.
44. Shindo,K., Takaori-Kondo,A., Kobayashi,M., Abudu,A., Fukunaga,K. and Uchiyama,T. (2003) The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem., 278, 44412-44416.
45. Demaison,C., Parsley,K., Brouns,G., Scherr,M., Battmer,K., Kinnon,C., Grez,M. and Thrasher,A.J. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther., 13, 803-813.
46. Besnier,C., Takeuchi,Y. and Towers,G. (2002) Restriction of lentivirus in monkeys. Proc. Natl Acad. Sci. USA, 99, 11920-11925.
47. Naldini,L., Blomer,U., Gallay,P., Ory,D., Mulligan,R., Gage,F.H., Verma,I.M. and Trono,D. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272, 263-267.
48. Gu,Y. and Sundquist,W.I. (2003) Good to CU. Nature, 424, 21-22.
49. Vartanian,J.P., Sommer,P. and Wain-Hobson,S. (2003) Death and the retrovirus. Trends Mol. Med., 9, 409-413.
50. Noguchi,C., Ishino,H., Tsuge,M., Fujimoto,Y., Imamura,M., Takahashi,S. and Chayama,K. (2005) G to A hypermutation of hepatitis B virus. Hepatology, 41, 626-633.
51. Rosler,C., Kock,J., Malim,M.H., Blum,H.E. and von Weizsacker,F. (2004) Comment on 'Inhibition of hepatitis B virus replication by APOBEC3G'. Science, 305, 1403.
52. Turelli,P., Mangeat,B., Jost,S., Vianin,S. and Trono,D. (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science, 303, 1829.
53. Newman,E.N., Holmes,R.K., Craig,H.M., Klein,K.C., Lingappa,J.R., Malim,M.H. and Sheehy,A.M. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol., 15, 166-170.
54. Sawyer,S.L., Emerman,M. and Malik,H.S. (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol., 2, E275.
55. Muramatsu,M., Kinoshita,K., Fagarasan,S., Yamada,S., Shinkai,Y. and Honjo,T. (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell, 102, 553-563.
56. Neuberger,M.S., Harris,R.S., Di Noia,J. and Petersen-Mahrt,S.K. (2003) Immunity through DNA deamination. Trends Biochem. Sci., 28, 305-312.
57. Chaudhuri,J., Tian,M., Khuong,C., Chua,K., Pinaud,E. and Alt,F.W. (2003) Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature, 422, 726-730.
58. Pham,P., Bransteitter,R., Petruska,J. and Goodman,M.F. (2003) Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature, 424, 103-107.
59. Beale,R.C., Petersen-Mahrt,S.K., Watt,I.N., Harris,R.S., Rada,C. and Neuberger,M.S. (2004) Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: Correlation with mutation spectra in vivo. J. Mol. Biol., 337, 585-596.
60. Zarrin,A.A., Alt,F.W., Chaudhuri,J., Stokes,N., Kaushal,D., Du Pasquier,L. and Tian,M. (2004) An evolutionarily conserved target motif for immunoglobulin class-switch recombination. Nature Immunol., 5, 1275-1281.
61. Wagner,S.D., Milstein,C. and Neuberger,M.S. (1995) Codon bias targets mutation. Nature, 376, 732.
62. Bransteitter,R., Pham,P., Calabrese,P. and Goodman,M.F. (2004) Biochemical analysis of hypermutational targeting by wild type and mutant activation-induced cytidine deaminase. J. Biol. Chem., 279, 51612-51621.
63. Cumbers,S.J., Williams,G.T., Davies,S.L., Grenfell,R.L., Takeda,S., Batista,F.D., Sale,J.E. and Neuberger,M.S. (2002) Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines. Nat. Biotechnol., 20, 1129-1134.
64. Martin,A., Bardwell,P.D., Woo,C.J., Fan,M., Shulman,M.J. and Scharff,M.D. (2002) Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature, 415, 802-806.
65. Wang,L., Jackson,W.C., Steinbach,P.A. and Tsien,R.Y. (2004) Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc. Natl Acad. Sci. USA, 101, 16745-16749.